Vor Bio (VOR) announced the appointment of Jeremy Sokolove, M.D., as Chief Medical Officer. Most recently, Dr. Sokolove served as Chief Medical Officer In-Residence at Roivant Sciences (ROIV)
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR:
- Vor Bio says telitacicept shows sustained efficacy in China Phase 3 study
- Vor Bio price target adjusted to $55 at H.C. Wainwright after reverse split
- Vor Biopharma Unveils Promising Phase 3 Trial Results
- Major Moves: Fifth Third, HEICO, Transdigm, Cytokinetics, Vor Biopharma
- Vor Bio announces Phase 3 study on telitacicept in SLE met primary endpoint